REACTOME does not include ARK5 within the members of the Glucose Metabolism Pathway, therefore this is an independent supportive finding of glucose metabolism as a therapeutic target in osteosarcoma, potentially through ARK5 inhibition. The gene discussed is NUAK1; the disease is osteosarcoma.